Solara Active Pharma Sciences Ltd. (IN:SOLARA)
:SOLARA
Want to see IN:SOLARA full AI Analyst Report?
SOLARA Stock Chart & Stats
₹582.80
-₹9.20(-1.31%)
At close: 4:00 PM EST
₹582.80
-₹9.20(-1.31%)
Day’s Range― - ―
52-Week Range₹422.85 - ₹734.20
Previous CloseN/A
Volume86.95K
Average Volume (3M)37.94K
Market Cap
₹27.69B
Enterprise Value₹34.00B
Total Cash (Recent Filing)₹169.30M
Total Debt (Recent Filing)₹6.46B
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.59
Shares Outstanding48,171,562
10 Day Avg. Volume26,889
30 Day Avg. Volume37,944
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.50
Price to Sales (P/S)1.37
P/FCF Ratio211.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)31.4
Revenue Forecast (FY)₹17.95B
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryRebounding revenue (+13.5% in FY2026) signals regained demand and market share for Solara’s API and CDMO offerings. Durable top-line recovery supports capacity utilization and long-term customer relationships, underpinning sustainable scale economics if the firm maintains quality and regulatory compliance.
Improving LeverageMaterial reduction in leverage (D/E ~0.55x) strengthens the balance sheet, lowering interest burden and increasing financial flexibility. This improves ability to fund compliance, capex, or strategic investments and reduces refinancing risk over the medium term, supporting operational resilience.
API / CDMO Business ModelA core API and CDMO model serves global pharma customers and benefits from sticky supply contracts, recurring orders, and regulatory barriers that limit new entrants. Export-driven revenue to regulated markets supports long-term demand and potential for margin expansion with higher-value custom synthesis work.
Bears Say
Net Loss / Inconsistent ProfitabilityA residual net loss despite revenue growth indicates earnings instability and weak returns on capital. Persistent or recurring small losses can erode investor confidence, limit retained earnings accumulation, and constrain reinvestment capacity critical for regulatory compliance and capacity upgrades required in pharma manufacturing.
Volatile Gross MarginsLarge swings in gross margin point to exposure to pricing pressure, product mix shifts, or cost volatility in feedstocks and production. Such instability undermines predictability of operating profitability and complicates long-term planning for capacity utilization and investment in higher-value CDMO capabilities.
Weak Cash GenerationSeverely reduced free cash flow and volatile operating cash weaken the company’s ability to self-fund capex, regulatory spending, and working-capital needs. Over time, constrained cash conversion raises reliance on external financing and limits resilience to product-specific or regulatory shocks in the pharma supply chain.
Solara Active Pharma Sciences Ltd. News
SOLARA FAQ
What was Solara Active Pharma Sciences Ltd.’s price range in the past 12 months?
Solara Active Pharma Sciences Ltd. lowest stock price was ₹422.85 and its highest was ₹734.20 in the past 12 months.
What is Solara Active Pharma Sciences Ltd.’s market cap?
Solara Active Pharma Sciences Ltd.’s market cap is ₹27.69B.
When is Solara Active Pharma Sciences Ltd.’s upcoming earnings report date?
Solara Active Pharma Sciences Ltd.’s upcoming earnings report date is Jul 30, 2026 which is in 70 days.
How were Solara Active Pharma Sciences Ltd.’s earnings last quarter?
Solara Active Pharma Sciences Ltd. released its earnings results on May 15, 2026. The company reported ₹2.2 earnings per share for the quarter, beating the consensus estimate of N/A by ₹2.2.
Is Solara Active Pharma Sciences Ltd. overvalued?
According to Wall Street analysts Solara Active Pharma Sciences Ltd.’s price is currently Overvalued.
Does Solara Active Pharma Sciences Ltd. pay dividends?
Solara Active Pharma Sciences Ltd. pays a Notavailable dividend of ₹3 which represents an annual dividend yield of N/A. See more information on Solara Active Pharma Sciences Ltd. dividends here
What is Solara Active Pharma Sciences Ltd.’s EPS estimate?
Solara Active Pharma Sciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solara Active Pharma Sciences Ltd. have?
Solara Active Pharma Sciences Ltd. has 48,171,562 shares outstanding.
What happened to Solara Active Pharma Sciences Ltd.’s price movement after its last earnings report?
Solara Active Pharma Sciences Ltd. reported an EPS of ₹2.2 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 14.324%.
Which hedge fund is a major shareholder of Solara Active Pharma Sciences Ltd.?
Currently, no hedge funds are holding shares in IN:SOLARA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solara Active Pharma Sciences Ltd.
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India. The company offers APIs for anesthetics, anthelmintic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-viral, antibiotic, anticoagulant, anticonvulsant, antidepressant, antiemetic, antiepileptic, antifungal, antigout agent, antihistamine, antihyperlipoproteinemic, antimalarial, antimycotic, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antitussive, antiulcerative, anxiolytic, bile acid analogue, calcimimetic agent, cardiovascular agent, central nervous system agent, chronic alcoholism, chronic kidney disease, dopamine receptor antagonist, folate analog, hyperkalaemia, immunosuppressant, lipid regulating agent, loop diuretic, muscarinic agonist, neuromuscular, OAB treatment, phenylalanine reducer, recovery of stroke, tardive dyskinesia, treatment of glaucoma and hyperphosphatemia, tropical anti-infective, and type-II diabetes therapeutic categories. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical services, impurity synthesis, and regulatory support. In addition, the company exports its products. It operates in the Asia Pacific, Europe, North America, South America, and internationally. The company was formerly known as SSL Pharma Sciences Limited and changed its name to Solara Active Pharma Sciences Limited in March 2017. Solara Active Pharma Sciences Limited was incorporated in 2017 and is based in Chennai, India.
Technical Analysis
Granules India Limited
―
Hikal Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Strides Pharma Science Ltd
―
Unichem Laboratories Limited
―